Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
2.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
3.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
4.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
6.

A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.

Shey M, Kongnyuy EJ, Shang J, Wiysonge CS.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005481. doi: 10.1002/14651858.CD005481.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;3:CD005481.

PMID:
19588374
7.

Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.

Figgitt DP, Plosker GL.

Drugs. 2000 Aug;60(2):481-516. Review.

PMID:
10983742
8.

Perspectives on HAART: switch maintenance therapy.

Leen CL.

Int J STD AIDS. 2003 Sep;14(9):577-82. Review.

PMID:
14511491
9.

Delavirdine: a review of its use in HIV infection.

Scott LJ, Perry CM.

Drugs. 2000 Dec;60(6):1411-44. Review.

PMID:
11152019
10.

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Le Tiec C, Barrail A, Goujard C, Taburet AM.

Clin Pharmacokinet. 2005;44(10):1035-50. Review.

PMID:
16176117
11.

Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Kryst J, Kawalec P, Pilc A.

PLoS One. 2015 May 1;10(5):e0124279. doi: 10.1371/journal.pone.0124279. eCollection 2015. Review.

12.

Clinical uses of non-nucleoside reverse transcriptase inhibitors.

Harris M, Montaner JS.

Rev Med Virol. 2000 Jul-Aug;10(4):217-29. Review.

PMID:
10891870
13.

Efficacy of highly active antiretroviral therapy in HIV-1 infected children.

van Rossum AM, Fraaij PL, de Groot R.

Lancet Infect Dis. 2002 Feb;2(2):93-102. Review.

PMID:
11901656
14.
15.

Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.

Penazzato M, Giaquinto C.

Drugs. 2011 Nov 12;71(16):2131-49. doi: 10.2165/11597680-000000000-00000. Review.

PMID:
22035514
16.

Efavirenz.

Adkins JC, Noble S.

Drugs. 1998 Dec;56(6):1055-64; discussion 1065-6. Review.

PMID:
9878993
17.

Releasing the true power of protease inhibitors.

Raffi F.

Int J STD AIDS. 2003 Oct;14 Suppl 1:29-33. Review.

PMID:
14617401
18.
19.

The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.

Pérez-Molina JA, Domingo P, Martínez E, Moreno S.

J Antimicrob Chemother. 2008 Aug;62(2):234-45. doi: 10.1093/jac/dkn191. Epub 2008 May 14. Review.

PMID:
18480167
20.

Efavirenz for HIV-1 infection in adults: an overview.

Fortin C, Joly V.

Expert Rev Anti Infect Ther. 2004 Oct;2(5):671-84. Review.

PMID:
15482231

Supplemental Content

Support Center